You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

365 Results
Dans tout l’Ontario, les centres de cancérologie, les hôpitaux et les cliniques proposent une vaste gamme de services de dépistage, de diagnostic et...
Guidelines and Advice
Status: Current
Updated
Mar 2025
Guidelines and Advice
Status: In-Review
ID: 19-4
May 2015
Guidelines and Advice
Status: Current
ID: PET 2024-1
Updated
Mar 2025
Guidelines and Advice
Status: In-Review
ID: 15-12
Version: 2
Jan 2015
Document
New
Apr 2025
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    enzalutamide - For the treatment of metastatic castrate-resistant prostate cancer (mCRPC), with specific clinical criteria
Exceptional Access Program
    enzalutamide - For the treatment of high risk non-metastatic castration-resistant prostate cancer (nmCRPC), with specific clinical criteria
Exceptional Access Program
    enzalutamide - For the treatment metastatic castration sensitive prostate cancer (mCSPC), with specific clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
enzalutamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2025
Document
New
May 2025
Document
New
May 2025
Document
New
May 2025
Document
New
May 2025
Document
New
May 2025

Pages